Risk factors for hormone receptor-defined breast cancer in postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 12, 2006, Pages 2482-2488

  Rosenberg, Lena U ^a   Einarsdóttir, Kristjana ^a   Friman, Erika Isaksson ^b   Wedrén, Sara ^a   Dickman, Paul W ^a   Hall, Per ^a   Magnusson, Cecilia ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN RECEPTOR; HORMONE RECEPTOR; LEVONORGESTREL; NORETHISTERONE ACETATE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MATERNAL AGE; MONOTHERAPY; ONSET AGE; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; TUMOR VOLUME; WEIGHT GAIN;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CASE-CONTROL STUDIES; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; SWEDEN; WEIGHT GAIN;

EID: 33845967808     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0489     Document Type: Article

References (38)

1. Trichopoulos D, Lagiou P, Adami HO. Towards an integrated model for breast cancer etiology: the crucial role of the number of mammary tissue-specific stem cells. Breast Cancer Res 2005;7:13-7.
2. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82.
3. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004;13:1558-68.
4. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin- replacement therapy. Int J Cancer 1999;81:339-44.
5. Magnusson C, Baron J, Persson I, et al. Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer 1998;76:29-34.
6. Brouillet JP, Dujardin MA, Chalbos D, et al. Analysis of the potential contribution of estrogen receptor (ER) β in ER cytosolic assay of breast cancer. Int J Cancer 2001;95:205-8.
7. Gapstur SM, Potter JD, Drinkard C, Folsom AR. Synergistic effect between alcohol and estrogen replacement therapy on risk of breast cancer differs by estrogen/progesterone receptor status in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev 1995;4:313-8.
8. Suzuki R, Ye W, Rylander-Rudqvist T, Saji S, Colditz GA, Wolk A. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study. J Natl Cancer Inst 2005;97:1601-8.
9. Ursin G, Bernstein L, Lord SJ, et al. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology. Br J Cancer 2005;93:364-71.
10. Cooper JA, Rohan TE, Cant EL, Horsfall DJ, Tilley WD. Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study. Br J Cancer 1989;59:119-25.
11. Yoo KY, Tajima K, Miura S, et al. Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. Am J Epidemiol 1997;146:307-14.
12. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev 2003;12:1053-60.
13. Kreiger N, King WD, Rosenberg L, Clarke EA, Palmer JR, Shapiro S. Steroid receptor status and the epidemiology of breast cancer. Ann Epidemiol 1991;1:513-23.
14. Wohlfahrt J, Mouridsen H, Andersen PK, Melbye M. Reproductive risk factors for breast cancer by receptor status, histology, laterality, and location. Int J Cancer 1999;81:49-55.
15. Hislop TG, Coldman AJ, Elwood JM, Skippen DH, Kan L. Relationship between risk factors for breast cancer and hormonal status. Int J Epidemiol 1986;15:469-76.
16. Potter JD, Cerhan JR, Sellers TA, et al. Progesterone and estrogen receptors and mammary neoplasia in the Iowa Women's Health Study: how many kinds of breast cancer are there? Cancer Epidemiol Biomarkers Prev 1995;4:319-26.
17. McCredie MR, Dite GS, Southey MC, Venter DJ, Giles GG, Hopper JL. Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. Br J Cancer 2003;89:1661-3.
18. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 2004;96:218-28.
19. Enger SM, Ross RK, Paganini-Hill A, Carpenter CL, Bernstein L. Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol Biomarkers Prev 2000;9:681-7.
20. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol 2000;151:703-14.
21. Suzuki R, Rylander-Rudqvist T, Ye W, Saji S, Wolk A. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study. Int J Cancer 2006;119:1683-9.
22. Yoo K, Tajima K, Park S, et al. Postmenopausal obesity as a breast cancer risk factor according to estrogen and progesterone receptor status (Japan). Cancer Lett 2001;167:57-63.
23. Sellers TA, Davis J, Cerhan JR, et al. Interaction of waist/hip ratio and family history on the risk of hormone receptor-defined breast cancer in a prospective study of postmenopausal women. Am J Epidemiol 2002;155:225-33.
24. Feigelson HS, Patel AV, Teras LR, Gansler T, Thun MJ, Calle EE. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer 2006;107:12-21.
25. Lukanova A, Lundin E, Zeleniuch-Jacquotte A, et al. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. Eur J Endocrinol 2004;150:161-71.
26. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001;8:47-61.
27. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227-38.
28. Daling JR, Malone KE, Doody DR, et al. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. Cancer Epidemiol Biomarkers Prev 2003;12:1175-81.
29. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63.
30. Ursin G, Tseng CC, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol 2002;20:699-706.
31. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027-32.
32. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004;101:1490-500.
33. Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M. Postmenopausal hormone therapy and breast cancer risk: the multiethnic cohort. Int J Cancer 2006;118:1285-91.
34. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
35. Wood AM, White IR, Hillsdon M, Carpenter J. Comparison of imputation and modelling methods in the analysis of a physical activity trial with missing outcomes. Int J Epidemiol 2005;34:89-99.
36. Hernan MA, Hernandez-Diaz S, Werler MM, Mitchell AA. Causal knowledge as a prerequisite for confounding evaluation: an application to birth defects epidemiology. Am J Epidemiol 2002;155:176-84.
37. Ferno M, Bendahl PO, Brisfors A, et al.; Swedish Society of Cancer Study Group. Intra- and inter-laboratory reproducibility of estrogen and progesterone receptor enzyme immunoassay in breast cancer cytosol samples-a Swedish multicenter study. Acta Oncol 1997;36:793-8.
38. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1:43-6.